Peringatan Keamanan

In the event of an overdose, patients may experience hypotensionFDA Label. Blood pressure and heart rate should be controlled by having the patient lie down or by treating with volume expanders or if necessary vasopressorsFDA Label. Patients should be monitored for renal functionFDA Label. Because terazosin is highly protein bound, dialysis is unlikely to provide benefit to overdosing patientsFDA Label.

The oral LD50 in mice is 5500mg/kgMSDS.

Terazosin

DB01162

small molecule approved

Deskripsi

Terazosin is a quinazoline derivative alpha-1-selective adrenergic blocking agent indicated for benign prostatic hyperplasia and hypertensionFDA Label^A176831. Terazosin blocks adrenaline's action on alpha-1 adrenergic receptors, causing relaxation of smooth muscle in blood vessels and the prostate^A176837.

Struktur Molekul 2D

Berat 387.4329

Wujud solid

Peta Jejaring Molekuler

Obat Target Gen Interaksi Enzim Transporter Carrier

Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

1. Pendahuluan & Konsep

Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).

2. Sumber Data (Validasi)

Data Obat: Diekstraksi dari elemen drugbank-id dan name pada skema XML DrugBank.
Target Protein: Diambil dari elemen targets/target yang memuat polipeptida sasaran.
Genetik: Disinkronisasi dari sub-elemen gene-name dan varian snp-effects.
Genetik: Jumlah titik node dibatasi pada maksimal 10 (Slice=10) interaksi untuk menghindari tumpukan data.

3. Algoritma Visualisasi

Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.

4. Legenda Visual

Obat Utama (Pusat Analisis)

Target Protein (Mekanisme)

Gen (Faktor Genetik)

Metode ini mendukung analisis Precision Medicine dan evaluasi risiko Drug-Drug Interaction (DDI).

Profil Farmakokinetik

Waktu Paruh (Half-Life) Terazosin has a mean half life 12 hours though this can be as high as 14 hours in patients over 70 years and as low as 11.4 hours in patients 20 to 39 years old[FDA Label][A176831].

Volume Distribusi 25L to 30L[A176831].

Klirens (Clearance) Plasma clearance is 80mL/min and renal clearance is 10mL/min[A176831].

Absorpsi

Approximately 90%^A176831.

Metabolisme

The majority of terazosin is hepatically metabolized^A176831. The metabolites recovered include 6-O-demethyl terazosin, 7-O-methyl terazosin, a piperozine derivative, and a diamine derivative^A176831.

Rute Eliminasi

Approximately 10% of the oral dose is excreted unchanged in the urine and approximately 20% is excreted in the fecesFDA Label^A176831. 40% of the total dose is eliminated in urine and 60% of the total dose is eliminated in the fecesFDA Label^A176831.

Interaksi Makanan

1 Data

1. Take with or without food. A meal does not significantly affect the extent of absorption but delays Tmax by 40 minutes.

Interaksi Obat

699 Data

Duloxetine	The risk or severity of orthostatic hypotension and syncope can be increased when Terazosin is combined with Duloxetine.
Levodopa	The risk or severity of hypotension and orthostatic hypotension can be increased when Terazosin is combined with Levodopa.
Risperidone	Terazosin may increase the hypotensive activities of Risperidone.
Amifostine	Terazosin may increase the hypotensive activities of Amifostine.
Diazoxide	Diazoxide may increase the hypotensive activities of Terazosin.
Methylphenidate	Methylphenidate may decrease the antihypertensive activities of Terazosin.
Dexmethylphenidate	Dexmethylphenidate may decrease the antihypertensive activities of Terazosin.
Obinutuzumab	Terazosin may increase the hypotensive activities of Obinutuzumab.
Pentoxifylline	Pentoxifylline may increase the hypotensive activities of Terazosin.
Rituximab	Terazosin may increase the hypotensive activities of Rituximab.
Desmopressin	Desmopressin may decrease the antihypertensive activities of Terazosin.
Methysergide	Methysergide may decrease the antihypertensive activities of Terazosin.
Atomoxetine	Atomoxetine may decrease the antihypertensive activities of Terazosin.
Zolmitriptan	Zolmitriptan may decrease the antihypertensive activities of Terazosin.
Protriptyline	Protriptyline may decrease the antihypertensive activities of Terazosin.
Methylergometrine	Methylergometrine may decrease the antihypertensive activities of Terazosin.
Mirtazapine	Mirtazapine may decrease the antihypertensive activities of Terazosin.
Buspirone	Buspirone may decrease the antihypertensive activities of Terazosin.
Doxapram	Doxapram may decrease the antihypertensive activities of Terazosin.
Atropine	Atropine may decrease the antihypertensive activities of Terazosin.
Lisuride	Lisuride may decrease the antihypertensive activities of Terazosin.
Alfentanil	Alfentanil may decrease the antihypertensive activities of Terazosin.
Fentanyl	Fentanyl may decrease the antihypertensive activities of Terazosin.
Phenmetrazine	Phenmetrazine may decrease the antihypertensive activities of Terazosin.
Almotriptan	Almotriptan may decrease the antihypertensive activities of Terazosin.
Naratriptan	Naratriptan may decrease the antihypertensive activities of Terazosin.
Rizatriptan	Rizatriptan may decrease the antihypertensive activities of Terazosin.
Dopamine	Dopamine may decrease the antihypertensive activities of Terazosin.
Frovatriptan	Frovatriptan may decrease the antihypertensive activities of Terazosin.
Methoxyflurane	Methoxyflurane may decrease the antihypertensive activities of Terazosin.
Ergoloid mesylate	Ergoloid mesylate may decrease the antihypertensive activities of Terazosin.
Dutasteride	Dutasteride may decrease the antihypertensive activities of Terazosin.
Desipramine	Desipramine may decrease the antihypertensive activities of Terazosin.
Finasteride	Finasteride may decrease the antihypertensive activities of Terazosin.
Yohimbine	Yohimbine may decrease the antihypertensive activities of Terazosin.
Solifenacin	Solifenacin may decrease the antihypertensive activities of Terazosin.
Epicaptopril	Epicaptopril may decrease the antihypertensive activities of Terazosin.
1-benzylimidazole	1-benzylimidazole may decrease the antihypertensive activities of Terazosin.
Lysergic acid diethylamide	Lysergic acid diethylamide may decrease the antihypertensive activities of Terazosin.
Amineptine	Amineptine may decrease the antihypertensive activities of Terazosin.
Flibanserin	Flibanserin may decrease the antihypertensive activities of Terazosin.
Naluzotan	Naluzotan may decrease the antihypertensive activities of Terazosin.
Cariprazine	Cariprazine may decrease the antihypertensive activities of Terazosin.
Mianserin	Mianserin may decrease the antihypertensive activities of Terazosin.
Esmirtazapine	Esmirtazapine may decrease the antihypertensive activities of Terazosin.
Vilazodone	Vilazodone may decrease the antihypertensive activities of Terazosin.
Nitrous oxide	Nitrous oxide may decrease the antihypertensive activities of Terazosin.
Saralasin	Saralasin may decrease the antihypertensive activities of Terazosin.
Cinitapride	Cinitapride may decrease the antihypertensive activities of Terazosin.
Tyramine	Tyramine may decrease the antihypertensive activities of Terazosin.
Ifenprodil	Ifenprodil may decrease the antihypertensive activities of Terazosin.
Dimetacrine	Dimetacrine may decrease the antihypertensive activities of Terazosin.
Butriptyline	Butriptyline may decrease the antihypertensive activities of Terazosin.
Cannabidiol	Cannabidiol may decrease the antihypertensive activities of Terazosin.
Vortioxetine	Vortioxetine may decrease the antihypertensive activities of Terazosin.
Dosulepin	Dosulepin may decrease the antihypertensive activities of Terazosin.
Moxisylyte	Moxisylyte may decrease the antihypertensive activities of Terazosin.
Tianeptine	Tianeptine may decrease the antihypertensive activities of Terazosin.
Oxaprotiline	Oxaprotiline may decrease the antihypertensive activities of Terazosin.
Dihydroergocornine	Dihydroergocornine may decrease the antihypertensive activities of Terazosin.
Atipamezole	Atipamezole may decrease the antihypertensive activities of Terazosin.
Tetrahydrocannabivarin	Tetrahydrocannabivarin may decrease the antihypertensive activities of Terazosin.
Piclozotan	Piclozotan may decrease the antihypertensive activities of Terazosin.
Siponimod	Siponimod may decrease the antihypertensive activities of Terazosin.
Idazoxan	Idazoxan may decrease the antihypertensive activities of Terazosin.
Opipramol	Opipramol may decrease the antihypertensive activities of Terazosin.
Tramazoline	Tramazoline may decrease the antihypertensive activities of Terazosin.
Amitriptylinoxide	Amitriptylinoxide may decrease the antihypertensive activities of Terazosin.
Dibenzepin	Dibenzepin may decrease the antihypertensive activities of Terazosin.
Quinupramine	Quinupramine may decrease the antihypertensive activities of Terazosin.
Trichloroethylene	Trichloroethylene may decrease the antihypertensive activities of Terazosin.
Fenozolone	Fenozolone may decrease the antihypertensive activities of Terazosin.
Dihydroergocristine	Dihydroergocristine may decrease the antihypertensive activities of Terazosin.
Melitracen	Melitracen may decrease the antihypertensive activities of Terazosin.
Dihydroergocryptine	Dihydroergocryptine may decrease the antihypertensive activities of Terazosin.
Terguride	Terguride may decrease the antihypertensive activities of Terazosin.
Lofepramine	Lofepramine may decrease the antihypertensive activities of Terazosin.
Xenon	Xenon may decrease the antihypertensive activities of Terazosin.
Iprindole	Iprindole may decrease the antihypertensive activities of Terazosin.
Buflomedil	Buflomedil may decrease the antihypertensive activities of Terazosin.
Metergoline	Metergoline may decrease the antihypertensive activities of Terazosin.
Diethyl ether	Diethyl ether may decrease the antihypertensive activities of Terazosin.
Imipramine oxide	Imipramine oxide may decrease the antihypertensive activities of Terazosin.
Mefenorex	Mefenorex may decrease the antihypertensive activities of Terazosin.
5-methoxy-N,N-dimethyltryptamine	5-methoxy-N,N-dimethyltryptamine may decrease the antihypertensive activities of Terazosin.
Quinoline Yellow WS	Quinoline Yellow WS may decrease the antihypertensive activities of Terazosin.
Solriamfetol	Solriamfetol may decrease the antihypertensive activities of Terazosin.
Sufentanil	Sufentanil may decrease the antihypertensive activities of Terazosin.
Isoflurane	Isoflurane may decrease the antihypertensive activities of Terazosin.
Propofol	Propofol may decrease the antihypertensive activities of Terazosin.
Remifentanil	Remifentanil may decrease the antihypertensive activities of Terazosin.
Halothane	Halothane may decrease the antihypertensive activities of Terazosin.
Omapatrilat	Omapatrilat may decrease the antihypertensive activities of Terazosin.
Rescinnamine	Rescinnamine may decrease the antihypertensive activities of Terazosin.
Desflurane	Desflurane may decrease the antihypertensive activities of Terazosin.
Sevoflurane	Sevoflurane may decrease the antihypertensive activities of Terazosin.
Clomipramine	Clomipramine may decrease the antihypertensive activities of Terazosin.
Rotigotine	Rotigotine may decrease the antihypertensive activities of Terazosin.
Cyclosporine	Cyclosporine may decrease the antihypertensive activities of Terazosin.
Eletriptan	Eletriptan may decrease the antihypertensive activities of Terazosin.

Target Protein

Alpha-1A adrenergic receptor ADRA1A

Alpha-1B adrenergic receptor ADRA1B

Alpha-1D adrenergic receptor ADRA1D

Transforming growth factor beta-1 proprotein TGFB1

Voltage-gated inwardly rectifying potassium channel KCNH2 KCNH2

Voltage-gated inwardly rectifying potassium channel KCNH6 KCNH6

Voltage-gated inwardly rectifying potassium channel KCNH7 KCNH7

Referensi & Sumber

Synthesis reference: K. S. Keshava Murthy, Gamini Weeratunga, Tianhao Zhou, Bhaskar Reddy Guntoori, "Process for the manufacture of intermediates suitable to make doxazosin, terazosin, prazosin, tiodazosin and related antihypertensive medicines." U.S. Patent US5919931, issued September, 1986.

Artikel (PubMed)

PMID: 2872802
Sonders RC: Pharmacokinetics of terazosin. Am J Med. 1986 May 23;80(5B):20-4.
PMID: 23518907
Papadopoulos G, Vlachodimitropoulos D, Kyroudi A, Kouloukoussa M, Perrea D, Mitropoulos D: Terazosin treatment induces caspase-3 expression in the rat ventral prostate. J Clin Med Res. 2013 Apr;5(2):127-31. doi: 10.4021/jocmr1215w. Epub 2013 Feb 25.
PMID: 14767264
Roehrborn CG, Schwinn DA: Alpha1-adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasia. J Urol. 2004 Mar;171(3):1029-35.
PMID: 10503165
Na YJ, Guo YL, Gu FL: Clinical comparison of selective and non-selective alpha 1A-adrenoceptor antagonists for bladder outlet obstruction associated with benign prostatic hyperplasia: studies on tamsulosin and terazosin in Chinese patients. The Chinese Tamsulosin Study Group. J Med. 1998;29(5-6):289-304.
PMID: 11170131
Glassman DT, Chon JK, Borkowski A, Jacobs SC, Kyprianou N: Combined effect of terazosin and finasteride on apoptosis, cell proliferation, and transforming growth factor-beta expression in benign prostatic hyperplasia. Prostate. 2001 Jan 1;46(1):45-51.

Link

Contoh Produk & Brand

Produk: 245 • International brands: 9

Produk

Apo-terazosin

Tablet • 2 mg • Oral • Canada • Generic • Approved
Apo-terazosin

Tablet • 5 mg • Oral • Canada • Generic • Approved
Apo-terazosin

Tablet • 10 mg • Oral • Canada • Generic • Approved
Apo-terazosin

Tablet • 1 mg • Oral • Canada • Generic • Approved
Dom-terazosin

Tablet • 1 mg • Oral • Canada • Generic • Approved
Dom-terazosin

Tablet • 2 mg • Oral • Canada • Generic • Approved
Dom-terazosin

Tablet • 5 mg • Oral • Canada • Generic • Approved
Dom-terazosin

Tablet • 10 mg • Oral • Canada • Generic • Approved

Menampilkan 8 dari 245 produk.

International Brands

Blavin — Baliarda (Argentina)
Flumarc — Raffo (Argentina)
Fosfomic — Finadiet (Argentina)
Heitrin — Abbott (Germany; discontinued)
Hytrinex — Amdipharm (Sweden)
Itrin — Keryos (Italy)
Urodie — Keryos (Italy)
Vicard — Amdipharm (Austria)
Zayasel

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.